Replimune Group Prices Underwritten Offering Of 9.70 Mln Shares At $12.06/Shr; Shares Up
Replimune Group (REPL) priced an underwritten offering of 9.70 million common shares at $12.06 each, plus pre-funded warrants for 2.74 million shares at $12.0599 per warrant, for gross proceeds of about $150 million before fees. The offering is expected to close Aug. 11. REPL shares were up 11.18% to $13.41 on Nasdaq.
How this was made
The 30-second read
Why it matters
The disclosed offering terms (share count, price, warrant strike, and expected gross proceeds) create a clear near-term catalyst for trading, with dilution risk typically pressuring the stock into and around the closing date.
Market read
A priced equity raise with a defined close date is a tradable event due to dilution expectations and financing-risk repricing.
What to watch
The article does not state use of proceeds, existing cash burn, or whether the offering price implies a discount to recent trading beyond the snapshot, which can materially change dilution interpretation.
Background
Replimune Group is a clinical-stage biotech company; this report covers the pricing of an underwritten common-share offering plus pre-funded warrants.
Ticker impact
Replimune priced an underwritten offering of 9.70M shares at $12.06 and pre-funded warrants, expecting about $150M gross proceeds and closing Aug. 11.
Likely continued volatility around the Aug. 11 close, with dilution pressure offset by improved balance-sheet visibility.
The article discloses the exact offering size, price, warrant terms, and expected gross proceeds, which directly affect near-term supply/dilution expectations and financing outlook.
Market effects
Clinical-stage biotech names may see similar sentiment swings when equity offerings price, especially when proceeds are large relative to market cap.
Primarily Nasdaq small/mid-cap biotech flow and liquidity effects around the offering close.
Limited, as the event is company-specific and not a cross-market macro catalyst.
Counterpoint
The stock’s immediate strength after pricing implies the market may view the raise as de-risking runway rather than purely dilutive.
Key entities
- companyReplimune Group, Inc.
Clinical-stage biotech that priced an underwritten offering of common shares and pre-funded warrants.
